Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Change in Accured Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Change in Accured Expenses for 16 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 216.67% to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.9 million, a 271.46% decrease, with the full-year FY2024 number at $4.7 million, up 227.88% from a year prior.
  • Change in Accured Expenses was -$1.1 million for Q3 2025 at Plus Therapeutics, up from -$2.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q4 2022 to a low of -$3.6 million in Q1 2023.
  • A 5-year average of $44250.0 and a median of $3500.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 779.17% in 2024, then plummeted 5523.26% in 2025.
  • Plus Therapeutics' Change in Accured Expenses stood at -$461000.0 in 2021, then soared by 1075.49% to $4.5 million in 2022, then plummeted by 91.46% to $384000.0 in 2023, then soared by 779.17% to $3.4 million in 2024, then tumbled by 133.38% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Change in Accured Expenses are -$1.1 million (Q3 2025), -$2.8 million (Q2 2025), and -$2.4 million (Q1 2025).